As early as April, Russia began offering a coronavirus viral vector vaccine based on human adenovirus, a common cold virus, fused with the spike protein of SARS CoV-2 to select volunters Last week, a phase 1 trial on some military personnel was completed

As early as April, Russia began offering a coronavirus viral vector vaccine based on human adenovirus, a common cold virus, fused with the spike protein of SARS CoV-2 to select volunters

Last week, a phase 1 trial on some military personnel was completedhttps://t.co/YR1gqP1gcZ

— Scott Rose (@rprose) July 20, 2020